News
Newsfeed
News
Tuesday
January 19
USD
519.31
EUR
629.4
RUB
7.04
ME-USD
0.01
Show news feed

The COVID-19 vaccine effectiveness, developed by the American company Moderna, in the initial analysis, was 94.1%, CNBC reported

Over 30 thousand volunteers participated in the vaccine trials. And 196 of these people became infected with the coronavirus - these are 185 volunteers who received a placebo, and 11 people who received the vaccine. Thus, the effectiveness of the drug was 94.1%.

Moderna also assessed how its vaccine works for severe COVID-19 cases. Of the 30 severe cases of COVID-19 in the trial, none were in the group that received the vaccine, Moderna said. Additionally, there was one COVID -19-related death in the study that occurred in the placebo group, according to the company.

The effectiveness of the vaccine is independent of age, race, and gender, the company noted. Among those who received a placebo, one person died from the coronavirus.

Moderna also announced that it will apply for the use of its vaccine in the US on Nov.30. It will have to be reviewed by the Food and Drug Administration (FDA). Earlier, the pharmaceutical company Pfizer sent a request for registration of the vaccine in the US, which reported 94% effectiveness of its drug.

!
This text available in   Հայերեն and Русский
Print
Read more:
All
Photos